BioCentury article: CD38 Hat Trick

This article is also available in pdf format. Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates effector T cells. The CD38 space initially gained prominence based on the speedy development and commercial success of … Read More